期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

液体活检技术在乳腺癌诊治中的应用进展 被引量：7

下载PDF
导出
摘要 新一代检测技术液体活检相较于传统的组织活检具有操作简便、可重复性好、非侵入性等优势。液体活检的主要检测对象包括肿瘤标志物、人表皮生长因子受体-2（human epidermal growth factor receptor-2,HER-2）蛋白胞外段（extracellular domain,ECD）、循环肿瘤细胞（circulating tumor cells,CTCs）、循环肿瘤DNA等。肿瘤标志物的检测基本已成为临床应用的常规,但特异性有待提高。
作者 周金妹 史方浩 马艳 胡志远 王涛 江泽飞
机构地区 解放军第 国家纳米科学中心
出处 《实用肿瘤杂志》 CAS 2016年第5期414-418,共5页 Journal of Practical Oncology
基金 北京市科技计划课题(Z151100004015212)
关键词 乳腺肿瘤/诊断 乳腺肿瘤/治疗 CA-15-3抗原/血液 癌胚抗原/血液 肿瘤标记 生物学/血液 肿瘤循环细胞 基因 ERBB-2 DNA 肿瘤/血液
分类号 R737.9 [医药卫生—肿瘤] R730.4 [医药卫生—肿瘤]
  • 相关文献

参考文献33

  • 1Ravelli A, Reuben JM, Lanza F, et al. Breast cancer circu- lating biomarkers: advantages, drawbacks, and new in- sights [ J ] Turnout Biol,2015,36 (9) :6653 - 6665.
  • 2Lee JS, Park S, Park JM,et al. Elevated levels of preoper- ative CA 15-3 and CEA serum levels have independently poor prognostic significance in breast cancer[ J]. Ann On- en1,2013,24(5 ) : 1225 - 1231.
  • 3Lee JS, Park S, Park JM, et al. Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers [ J ]. Breast Cancer Res Treat, 2013,141 ( 3 ) :477 - 484.
  • 4Sturgeon CM, Dully M J, Stenman UH, et al. National A- cademy of Clinical Biochemistry laboratm'y medicine prac- tice guidelines for use of tumor markers in testicular, pros- tate, colorectal, breast, and ovarian cancers [ J ]. Clin Chem,2008,54(12) :el I -79.
  • 5Wang T, Zhou J, Zhang S, et al. Meaningful interpretation of serum HER2 ECD levels requires clear patient clinical background,and sel-ces several functions in the efficient management of breast eancer patients [ J ]. Clin Chim Ae- ta,2016,458:23 - 29.
  • 6Ludovini V, Gori S, Colozza M, et al. Evaluation of serum HER2 extracellular domain in early breast cancer pa- tients:correlation with elinicopathological parameters and survival [ J ]. Ann Oncol, 2008,19 ( 5 ) : 883 - 890.
  • 7Fehln T,Jiger W, Krimer S, et al. Prognostic significance f serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer [ J ]. Antieaneer Res, 2004, 24 (3b) : 1987 - 1992.
  • 8Colomer tl, Llombart-Cussac A, Lluch A, et al. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase 1I trial and predictive value of HER2 extraeellular domain [ J ]. Ann Oncol, 2004,15 ( 2 ) : 201 - 206.
  • 9Muller V,Witzel I, Luck HJ, et al. Prognostic and predic- tive impact of the HER-2/nen extraeellular domain (ECD) in the serum of patients treated with chemothera- py for metastatic breast cancer [ J J. Breast Caneer Res Treat, 2004,86 ( 1 ) : 9 - 18.
  • 10Lipton A, Ali SM, Leitzel K, et al. Elevated serum Her- 2/neu level predicts decreased response to hormone ther- apy in metastatic breast cancer[ J ]. J Clin Oneol,2002, 20(6) :1467 - 1472.

二级参考文献21

  • 1Krishnamurthy S, Cristofanilli M, Singh B, et al. Detection of mini- real residual disease in blood and bone marrow in early stage breast cancer. Cancer, 2010, 116(14) :3330-3337.
  • 2Miiller V, Alix-Panabieres C, Pantel K. Insights into minimal residual disease in cancer patients: implications for anti-cancer therapies. Eur J Cancer, 2010, 46(7) :1189-1197.
  • 3Ross JS, Slodkowska EA. Circulating and disseminated tumor cells in the management of breast cancer. Am J Clin Pathol, 2009, 132(2) : 237 -245.
  • 4Riethdorf S, Pantel K. Disseminated tumor cells in bone marrow and circulating tumor cells in blood of breast cancer patients : current state of detection and characterization. Pathobiology, 2008, 75 ( 2 ) : 140- 148.
  • 5Dawood S, Cristofanilli M. Integrating circulating tumor cell assays into the management of breast cancer. Curt Treat Options Oncol, 2007, 8(1) :89-95.
  • 6Chen Y, Zou TN, Wu ZP, et al. Detection of cytokeratin 19, human mammaglobin, and carcinoembryonie antigen-positive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer. Int J Biol Markers, 2010, 25(2) :59-68.
  • 7Saloustros E, Mavroudis D. Cytokeratin 19-positive circulating tumor cells in early breast cancer pi'ognosis. Future Oneol, 2010, 6 (2): 209-219.
  • 8Alvero AB, Burtness BA, Ercan AG, et al. Improved method for the detection of cytokeratin 19-positive cells in the peripheral blood of breast cancer patients. Lab Invest, 2004, 84(5 ) :658-661.
  • 9Hsieh HB, Marrinucci D, Bethel K, et al. High speed detection of circulating tumor cells. Biosens Bioelectron, 2006, 21 ( 10 ) : 1893- 1899.
  • 10Karl A, Tritsehler S, Hofmann S, et al. Perioperative search for circulating tumor cells in patients undergoing radical eystectomy for bladder cancer. Eur J Med Res, 2009,14( 11 ) :487-490.

共引文献2

同被引文献47

引证文献7

二级引证文献34

实用肿瘤杂志
2016年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部